MCID: CVD001
MIFTS: 60

Covid-19

Categories: Infectious diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Covid-19

MalaCards integrated aliases for Covid-19:

Name: Covid-19 11 28 41 43 14 75
Wuhan Seafood Market Pneumonia Virus Infection 11
Wuhan Coronavirus Infection 11
2019 Novel Coronavirus 11
Sars-Cov-2 Infection 11
2019-Ncov Infection 11
Covid19 11

Classifications:



External Ids:

Disease Ontology 11 DOID:0080600
MeSH 43 D000086382
NCIt 49 C171133
SNOMED-CT 68 840539006
UMLS 71 C5203670

Summaries for Covid-19

MedlinePlus: 41 COVID-19 (coronavirus disease 2019) is an illness caused by a virus. This virus is a coronavirus called SARS-CoV-2. It spreads when a person who has the infection breathes out droplets and very small particles that contain the virus. On this page, you'll find links to resources on important issues such as symptoms, risks, and how you can protect yourself and your family. We also have pages on: COVID-19 testing COVID-19 vaccines Post-COVID conditions (long COVID)

MalaCards based summary: Covid-19, also known as wuhan seafood market pneumonia virus infection, is related to long covid and non-severe covid-19. An important gene associated with Covid-19 is ACE2 (Angiotensin Converting Enzyme 2), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Lenalidomide and Deferoxamine have been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and t cells, and related phenotypes are homeostasis/metabolism and growth/size/body region

Disease Ontology: 11 A Coronavirus infection that is characterized by fever, cough and shortness of breath and that has material basis in SARS-CoV-2.

Wikipedia: 75 Coronavirus disease 2019 (COVID-19) is a contagious disease caused by a virus, the severe acute... more...

Related Diseases for Covid-19

Diseases in the Covid-19 family:

Severe Covid-19

Diseases related to Covid-19 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3267)
# Related Disease Score Top Affiliating Genes
1 long covid 33.1 TNF TMPRSS2 NRP1 IL6 IL1B FURIN
2 non-severe covid-19 33.1 TNNI3 TNF TMPRSS2 IL6 F3 CXCL8
3 severe covid-19 33.1 TNF TMPRSS2 TLR7 STING1 IL6 IL1B
4 severe acute respiratory syndrome 33.0 TNF TMPRSS2 IL6 IL1B FURIN F3
5 critical covid-19 33.0 TNF TMPRSS2 IL6 IL1B FURIN F3
6 adult respiratory distress syndrome 33.0 TNF TMPRSS2 IL6 IL1B CXCL8 ACE2
7 pneumonia 33.0 TNF IL6 IL1B CXCL8 CXCL10 CCL2
8 disease of mental health 32.9 TNF IL6 IL1B ACE
9 viral infectious disease 32.8 TNF TLR7 IL6 IL2RA IL1B CXCL8
10 anxiety 32.7 TNF IL6 IL1B CXCL8 ACE
11 respiratory failure 32.7 TNNI3 TNF TMPRSS2 TLR7 NLRP3 IL6
12 pulmonary embolism 32.6 TNNI3 F3 ACE2 ACE
13 middle east respiratory syndrome 32.5 TMPRSS2 IL6 FURIN DPP4 CXCL10 CTSL
14 myocarditis 32.4 TNNI3 TNF IL6 IL1B F3 CXCL8
15 mucormycosis 32.4 TNF IL6 ACE2
16 cerebrovascular disease 32.3 TNF IL6 IL1B ACE
17 lung disease 32.3 TNF STING1 IL6 IL1B CXCL8 CXCL10
18 stroke, ischemic 32.2 TNF IL6 IL1B F3 ACE2 ACE
19 toxic shock syndrome 32.2 TNF IL6 IL1B F3 CXCL8
20 bowel dysfunction 32.2 TNF IL6 IL1B ACE
21 vasculitis 32.2 TNF IL6 IL1B CXCL8 CCL2
22 diabetes mellitus, ketosis-prone 32.2 DPP4 ACE2 ACE
23 thrombocytopenia 32.1 TNF TLR7 NRP1 IL6 IL1B F3
24 dengue disease 32.1 TNF IL6 FURIN CXCL8
25 aspergillosis 32.1 TNF IL6 IL1B CXCL8 CXCL10
26 exanthem 32.1 TNF NLRP3 IL6 IL1B F3 CXCL8
27 sleep disorder 32.1 TNF IL6 IL1B CXCL8 ACE
28 chronic kidney disease 32.1 TNNI3 TNF IL6 IL1B ACE
29 appendicitis 32.1 TNF IL6 IL1B CXCL8 CCL2
30 disseminated intravascular coagulation 32.1 TNF IL6 F3 CXCL10 CCL2
31 common cold 32.1 TNF TMPRSS2 IL6 IL1B FURIN CXCL8
32 type 1 diabetes mellitus 32.1 TNF IL6 IL1B CXCL8 CXCL10 ACE
33 bell's palsy 32.1 TNF IL6 ACE2 ACE
34 autoimmune disease 32.0 TNF IL6 IL2RA IL1B F3 DPP4
35 viral pneumonia 32.0 TNF TMPRSS2 IL6 IL1B FURIN F3
36 pericarditis 32.0 TNNI3 TNF IL6 IL1B CXCL8 ACE2
37 cardiovascular system disease 32.0 TNF IL6 F3 CCL2 ACE2 ACE
38 pulmonary disease, chronic obstructive 32.0 TNF IL6 IL1B CXCL8 CXCL10 CCL2
39 measles 32.0 TLR7 IL6 IL2RA IL1B
40 diarrhea 32.0 TNF IL6 IL1B CXCL8
41 purpura 32.0 TNF IL6 IL1B F3 CXCL8
42 conjunctivitis 32.0 TNF NLRP3 IL6 IL2RA CXCL8 CCL2
43 ebola hemorrhagic fever 32.0 TNF TMPRSS2 TLR7 IL6 FURIN CXCL10
44 myelitis 32.0 TNF IL6 CXCL8 ACE2
45 inflammatory bowel disease 32.0 TNF IL6 IL2RA IL1B DPP4 CXCL8
46 alcohol use disorder 32.0 TNF IL6 IL1B ACE
47 multiple sclerosis 32.0 TNF IL6 IL2RA IL1B DPP4 CXCL8
48 interstitial lung disease 31.9 TNF STING1 IL6 IL1B CXCL8 CCL2
49 limb ischemia 31.9 IL6 F3 ACE
50 body mass index quantitative trait locus 11 31.9 TNF NLRP3 IL6 IL1B DPP4 CXCL8

Graphical network of the top 20 diseases related to Covid-19:



Diseases related to Covid-19

Symptoms & Phenotypes for Covid-19

MGI Mouse Phenotypes related to Covid-19:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.38 ACE ACE2 CCL2 CGAS CTSL CXCL10
2 growth/size/body region MP:0005378 10.36 ACE ACE2 CCL2 CTSL DPP4 F3
3 immune system MP:0005387 10.28 ACE ACE2 CCL2 CGAS CTSL CXCL10
4 cardiovascular system MP:0005385 10.27 ACE ACE2 CCL2 CTSL CXCL10 DPP4
5 cellular MP:0005384 10.25 ACE ACE2 CCL2 CTSL CXCL10 DPP4
6 muscle MP:0005369 10.21 ACE2 CCL2 CTSL F3 IL6 NRP1
7 neoplasm MP:0002006 10.18 ACE CCL2 F3 IL1B IL6 NRP1
8 digestive/alimentary MP:0005381 10.13 ACE2 CCL2 CTSL FURIN IL2RA IL6
9 liver/biliary system MP:0005370 10.1 ACE CCL2 CTSL FURIN IL6 NLRP3
10 hematopoietic system MP:0005397 10.09 ACE ACE2 CCL2 CGAS CTSL CXCL10
11 respiratory system MP:0005388 9.96 ACE2 DPP4 F3 IL2RA IL6 STING1
12 mortality/aging MP:0010768 9.93 ACE ACE2 CCL2 CGAS CTSL CXCL10
13 integument MP:0010771 9.32 ACE2 CCL2 CTSL F3 FURIN IL1B

Drugs & Therapeutics for Covid-19

Drugs for Covid-19 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1001)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenalidomide Approved Phase 4 191732-72-6 216326
2
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
3
Ravulizumab Approved, Investigational Phase 4 1803171-55-2
4
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
5
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
6
Losartan Approved Phase 4 114798-26-4 3961
7
Rivaroxaban Approved Phase 4 366789-02-8 9875401
8
Bromhexine Approved Phase 4 3572-43-8
9
Cyproheptadine Approved Phase 4 129-03-3 2913
10
Cefditoren Approved, Investigational Phase 4 117467-28-4, 104145-95-1 9870843
11
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
12
Bentonite Approved Phase 4
13
Ledipasvir Approved Phase 4 1256388-51-8 67505836
14
Fondaparinux Approved, Investigational Phase 4 114870-03-0, 104993-28-4 5282448 636380
15
Reviparin Approved, Investigational Phase 4 9041-08-1
16
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
17
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
18
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
19
Ticagrelor Approved Phase 4 274693-27-5 9871419
20
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
21
Dapagliflozin Approved Phase 4 461432-26-8 9887712
22
Hydrogen peroxide Approved, Vet_approved Phase 4 7722-84-1 784
23
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
24
Argatroban Approved, Investigational Phase 4 74863-84-6 152951 92722
25
Loperamide Approved Phase 4 53179-11-6 3955
26
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521 16682734
27
Morphine Approved, Investigational Phase 4 57-27-2 5288826
28
Glucosamine Approved, Investigational Phase 4 3416-24-8 318324 439213
29
Empagliflozin Approved Phase 4 864070-44-0 73151030 11949646
30
Ofatumumab Approved Phase 4 679818-59-8
31
Ertugliflozin Approved, Investigational Phase 4 1210344-57-2 75075340 44814423
32
Canagliflozin Approved Phase 4 842133-18-0 74323022 24812758
33
Chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
34
Nintedanib Approved Phase 4 656247-17-5 135423438 9809715
35
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
36
Remdesivir Approved, Investigational Phase 4 1809249-37-3 121304016
37
Montelukast Approved Phase 4 158966-92-8 5281040
38
Povidone-iodine Approved Phase 4 25655-41-8
39
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
40
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
41
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
42
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
43
Dextroamphetamine Approved, Illicit, Investigational Phase 4 51-64-9, 300-62-9 5826 3007
44
Echinacea Approved, Experimental Phase 4
45
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
46
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
47
Captopril Approved Phase 4 62571-86-2 44093
48
Bendroflumethiazide Approved Phase 4 73-48-3 2315
49
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
50
Verapamil Approved Phase 4 152-11-4, 52-53-9 2520

Interventional clinical trials:

(show top 50) (show all 8086)
# Name Status NCT ID Phase Drugs
1 COVID-19-associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19 Unknown status NCT04360824 Phase 4 Intermediate dose thromboprophylaxis;Standard of Care thromboprophylaxis
2 Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19. Multicenter, Randomized, Double-blind, Placebo-controlled Trial (CARR-COV-02) Unknown status NCT04521322 Phase 4 Iota-Carrageenan
3 Double-blind Randomized Controlled Clinical Trial of Low-dose Lenalidomide in the Treatment of COVID-19 Disease Unknown status NCT04361643 Phase 4 Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.;Placebo
4 Efficacy and Safety of Favipiravir Compared to the Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial Unknown status NCT04359615 Phase 4 Favipiravir;Hydroxychloroquine
5 Efficacy and Safety of Azithromycin Compared to the Base Therapeutic Regiment of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial Unknown status NCT04359316 Phase 4 Hydroxychloroquine;Azithromycin
6 Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Unknown status NCT04350684 Phase 4 Umifenovir;Interferon-β 1a;Lopinavir / Ritonavir;Single Dose of Hydroxychloroquine;Standards of Care
7 An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Unknown status NCT04350671 Phase 4 Interferon Beta-1A;Lopinavir / Ritonavir;Single Dose of Hydroxychloroquine
8 Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia Unknown status NCT04355026 Phase 4 Bromhexine Oral Tablet and/or hydroxychloroquine tablet
9 Comparison of Normal Saline, Hydrogen Peroxide, Chlorhexidine and Povidone-Iodine Mouth Rinses in COVID-19 Patients Unknown status NCT04603794 Phase 4 0.5% Povidone Iodine;0.12% Chlorhexidine Gluconate Mouth Rinse;1% Hydrogen Peroxide;0.9% Normal Saline
10 D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia Unknown status NCT04584580 Phase 4 low-molecular-weight heparin
11 The Use of Desferal and Adjuvants for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection: A Randomized Controlled Trial Unknown status NCT04389801 Phase 4 Desferal 500 MG Injection
12 The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study Unknown status NCT04286503 Phase 4 Carrimycin;lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate;basic treatment
13 Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19 Unknown status NCT04308317 Phase 4 Tetrandrine
14 Estudio Destinado a Valorar la Utilidad de Vitamina D Sobre Morbilidad y Mortalidad de la infección Por Virus SARS-COV-2 (COVID-19) en el Hospital Universitario Central de Asturias Unknown status NCT04552951 Phase 4 Cholecalciferol
15 Reducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial Unknown status NCT04417335 Phase 4
16 The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19 Unknown status NCT04468139 Phase 4 Quercetin;Zinc;Vitamin C
17 Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease Unknown status NCT04429867 Phase 4 Hydroxychloroquine;Placebo
18 Anticoagulation in Patients Suffering From COVID-19 Disease-The Anti-Co Trial Unknown status NCT04445935 Phase 4 Bivalirudin Injection;Standard treatment
19 Randomized, Open, Parallel, Single-center, Non-inferiority Clinical Trial, With an Active Control Group, Comparing Two Oral Prednisone Regimens With the Aim of Optimizing the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19 Infection Unknown status NCT04534478 Phase 4 Prednisone
20 Pilot Study of the Use of IVIG in Patients With Severe COVID-19 Infections Requiring Mechanical Ventilation and to Assess Their Biological Responses to IVIG Therapy Unknown status NCT04616001 Phase 4 IVIG
21 Effect of Pioglitazone on Inflammatory Response and Clinical Outcome in T2DM Patients With COVID-19 Unknown status NCT04604223 Phase 4 Pioglitazone 45 mg
22 Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial Unknown status NCT04334629 Phase 4 Ibuprofen
23 The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation Unknown status NCT04377750 Phase 4 Tocilizumab
24 Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword? Unknown status NCT04623385 Phase 4 The standard therapy
25 Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic Unknown status NCT04559074 Phase 4 Amlodipine
26 mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R) Unknown status NCT04390464 Phase 4 Ravulizumab;Baricitinib
27 Efficacy and Safety Study to Evaluate the Use of Nebulized Heparin in Patients With Severe Acute Respiratory Syndrome Covid-19 (SARS-CoV-2) Unknown status NCT04530578 Phase 4 Heparin sodium;Enoxaparin
28 Non-blinded, Randomized and Controlled Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19 Unknown status NCT04535700 Phase 4 Pioglitazone 30 mg
29 Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications Completed NCT04331600 Phase 4 Chloroquine phosphate
30 Safety and Immunogenicity of a Heterologous Immunization of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine Against COVID-19 in Chinese Healthy Population Completed NCT04833101 Phase 4
31 Safety and Immunogenicity of Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) inChinese Healthy Adults Aged 60 and Above: a Randomized, Observer-blind,Parallel-controlled Clinical Trial Completed NCT04952727 Phase 4
32 Immunogenicity and Safety of an Inactivated COVID-19 Vaccine for Prevention of COVID-19 in Healthy Population Aged 18 Years and Older Completed NCT04953325 Phase 4
33 Telmisartan for Treatment of COVID-19 Patients: an Open Label Randomized Trial Completed NCT04355936 Phase 4 Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.
34 An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection Completed NCT04345276 Phase 4 Danoprevir+Ritonavir
35 A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure. Completed NCT04326920 Phase 4 Sargramostim
36 A Post-marketing Clinical Study of the Inactivated SARS-CoV-2 Vaccine (Vero Cells) (Produced in Beijing): Immunogenicity and Safety Assessments in Patients With Hypertension and/or Diabetes Completed NCT05065879 Phase 4
37 A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting Completed NCT04370782 Phase 4 Hydroxychloroquine;Azithromycin;Zinc Sulfate;Doxycycline
38 Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial Completed NCT04353596 Phase 4 ACE inhibitor, angiotensin receptor blocker
39 A Randomized, Parallel-group Treatment, Quadruple Masked, Two-arm Study, to Assess the Effectiveness of Cod Liver Oil Compared to Placebo in the Prevention of Covid-19 and Airway Infections in Healthy Adults Completed NCT04609423 Phase 4
40 Fluoxetine to Reduce Intubation and Death After COVID19 Infection Completed NCT04377308 Phase 4 Fluoxetine
41 Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID) Completed NCT04367831 Phase 4 Enoxaparin Prophylactic Dose;Heparin Infusion;Heparin SC;Enoxaparin/Lovenox Intermediate Dose
42 An Open Clinical Trial to Evaluate Ganovo(Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection Completed NCT04291729 Phase 4 Ganovo+ritonavir+/-Interferon nebulization
43 Mouth Rinses Efficacy on Salivary SARS-CoV-2 Viral Load: A Randomized Clinical Trial Completed NCT04721457 Phase 4 Distilled Water;1% Povidone Iodine (PVP-I);1.5% Hydrogen Peroxide (H2O2);0.075% Cetylpyridinium Chloride (CPC);0.1% Sodium Hypochlorite
44 Prospective, Non-controlled Pilot Study to Evaluate the Efficacy and Safety of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia Completed NCT04709172 Phase 4 Cefditoren pivoxil 400mg
45 Pragmatic, Double-blind, Placebo-controlled Randomized Clinical Trial, Evaluating Hydroxychloroquine for Prevention of Hospitalization and Respiratory Complications in Non-hospitalized Patients With Confirmed or Probable COVID-19 Completed NCT04466540 Phase 4 Hydroxychloroquine;Placebo
46 A Double-blind, Randomized Clinical Trial to Evaluate the Lot-to-lot Consistency, Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Health Adults Aged 26-45 Years Completed NCT04894227 Phase 4
47 A Randomized, Double-Blinded Clinical Trial to Evaluate the Immunogenicity Using Additional Dose of Medium-dosage or High-dosage COVID-19 Vaccine (Vero Cell), Inactivated in Populations Who Have Completed Primary Immunization 5-9 Months Completed NCT05165966 Phase 4
48 Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity Completed NCT04441996 Phase 4
49 A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial Completed NCT04414267 Phase 4
50 Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Completed NCT04394117 Phase 4 Angiotensin Receptor Blockers

Search NIH Clinical Center for Covid-19

Cochrane evidence based reviews: covid-19

Genetic Tests for Covid-19

Genetic tests related to Covid-19:

# Genetic test Affiliating Genes
1 Covid-19 28

Anatomical Context for Covid-19

Organs/tissues related to Covid-19:

MalaCards : Lung, Kidney, T Cells, Endothelial, Liver, Bone Marrow, Brain

Publications for Covid-19

Articles related to Covid-19:

(show top 50) (show all 51892)
# Title Authors PMID Year
1
Non-invasive respiratory support in SARS-CoV-2 related acute respiratory distress syndrome: when is it most appropriate to start treatment? 62 41
36463178 2022
2
The effects of daily autobiographical memory training on memory bias, mood and stress resilience in dysphoric individuals. 41
36463266 2022
3
Effects of portable air cleaners and A/C unit fans on classroom concentrations of particulate matter in a non-urban elementary school. 41
36454721 2022
4
Trait Emotional Intelligence and Self-regulated Learning in University Students during the COVID-19 pandemic: the mediation role of Intolerance of Uncertainty and COVID-19 Perceived Stress. 62
36415560 2023
5
Heparin mimetics as potential intervention for COVID-19 and their bio-manufacturing. 62
36313216 2023
6
In vitro evaluation of the activity of teriflunomide against SARS-CoV-2 and the human coronaviruses 229E and OC43. 62
36437966 2023
7
Covid-19 vaccine hesitancy: Text mining, sentiment analysis and machine learning on COVID-19 vaccination Twitter dataset. 62
36092862 2023
8
Cerebellar infarction risk in a mild COVID-19 case. 62
36474520 2023
9
SARS-CoV-2 antibodies among health care workers from a children's hospital. 62
35984671 2023
10
Inactivation of two SARS-CoV-2 virus surrogates by electron beam irradiation on large yellow croaker slices and their packaging surfaces. 62
36091572 2023
11
Assessment of Admission COVID-19 Associated Hyperinflammation Syndrome Score in Critically-Ill COVID-19 Patients. 62
36213939 2023
12
COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity. 62
36252792 2023
13
The association between comorbidities and coronavirus disease 2019 hospitalization among people with HIV differs by age. 62
36111530 2023
14
Clinical characteristics and factors associated with ICU mortality during the first year of the SARS-Cov-2 pandemic in Romania: A prospective, cohort, multicentre study of 9000 patients. 62
36385096 2023
15
Disparities in the use of telehealth at the onset of the COVID-19 public health emergency. 62
33081595 2023
16
Analysis of serological surveys of antibodies to SARS-CoV-2 in the United States to estimate parameters needed for transmission modeling and to evaluate and improve the accuracy of predictions. 62
36208669 2023
17
An ultra-sensitive and specific nanoplasmonic-enhanced isothermal amplification platform for the ultrafast point-of-care testing of SARS-CoV-2. 62
36060034 2023
18
A COVID-19 nosocomial cluster in a university hospital in southern Italy: a social network analysis. 62
35442385 2023
19
Development of a high-speed bioaerosol elimination system for treatment of indoor air. 62
36407015 2023
20
Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: An international multi-centre observational cohort study. 62
36381999 2023
21
Hybrid Peptide-Agarose Hydrogels for 3D Immunoassays. 62
36152280 2023
22
Placental Morphology and Morphometry: Is It a Prerequisite for Future Pathological Investigations? 62
36460847 2023
23
Viral infections in pediatric brain tumor patients treated with targeted therapies. 62
36308741 2023
24
Qualitative Olfactory Dysfunction and COVID-19: An Evidence-Based Review with Recommendations for the Clinician. 62
35957578 2023
25
Diagnostic test property of transcription-reverse transcription concerted reaction reagent TRCReady® SARS-CoV-2 i using nasopharyngeal swab samples. 62
36183991 2023
26
Systematic identification of chemical components in Fufang Shuanghua oral liquid and screening of potential active components against SARS-CoV-2 protease. 62
36332330 2023
27
Efficacy and safety of Reyanning mixture in patients infected with SARS-CoV-2 Omicron variant: A prospective, open-label, randomized controlled trial. 62
36334390 2023
28
Co-infections among COVID-19 adult patients admitted to intensive care units: results from a retrospective study. 62
35195240 2023
29
Racial and Ethnic Disparity in Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 in Mississippi, USA. 62
35801262 2023
30
Strategies for ensuring required service level for COVID-19 herd immunity in Indian vaccine supply chain. 62
33776195 2023
31
Time series analysis of COVID-19 infection curve: A change-point perspective. 62
32836681 2023
32
#ENT: Otolaryngology Residency Programs Create Social Media Platforms to Connect With Applicants During COVID-19 Pandemic. 62
33355006 2023
33
National Narcissism predicts the Belief in and the Dissemination of Conspiracy Theories During the COVID-19 Pandemic: Evidence From 56 Countries. 62
34872399 2023
34
Potential Cardiac Tamponade Development Secondary to SARS-CoV-2 Infection. 62
36155201 2023
35
Audiological and vestibular symptoms following SARS-CoV-2 infection and COVID-19 vaccination in children aged 5-11 years. 62
36283164 2023
36
Factors influencing the immune response over 15 months after SARS-CoV-2 infection: A longitudinal population-wide study in the Faroe Islands. 62
35996938 2023
37
[Association of SARS-CoV-2 infection and administration of COVID-19 vaccines with alterations in the menstrual cycle. Literature review]. 62
36337070 2023
38
Functional consequences of SARS-CoV-2 infection in pregnant women, fetoplacental unit, and neonate. 62
36273675 2023
39
Relationship between KIR genotypes and HLA-ligands with SARS-CoV-2 infection in the Saudi population. 62
36338940 2023
40
Incidence of SARS-COV-2 infection among swimming athletes: data from real life in Apulia (Italy), July 2020/August 2021. 62
35452071 2023
41
SARS-CoV-2 Seroprevalence Among First Responders in Northeastern Ohio, 2020. 62
36114657 2023
42
Spatial and temporal dynamics of SARS-CoV-2: Modeling, analysis and simulation. 62
36124095 2023
43
COVID-19-associated coagulopathy in children: A multicenter observational cohort study. 62
36326142 2023
44
Structural modeling of protein ensembles between E3 RING ligases and SARS-CoV-2: The role of zinc binding domains. 62
36209710 2023
45
Delta SARS-CoV-2 variant is entirely substituted by the omicron variant during the fifth COVID-19 wave in Attica region. 62
36181801 2023
46
Antibody protection from SARS-CoV-2 respiratory tract exposure and infection. 62
36306828 2023
47
COVID-19 vaccine hesitancy: misinformation and perceptions of vaccine safety. 62
34325612 2022
48
The impact of COVID-19 lockdown on snacking habits, fast-food and alcohol consumption: A systematic review of the evidence. 62
34049747 2022
49
Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. 62
35132910 2022
50
The impact of COVID-19 on diet quality, food security and nutrition in low and middle income countries: A systematic review of the evidence. 62
34535329 2022

Variations for Covid-19

Expression for Covid-19

Search GEO for disease gene expression data for Covid-19.

Pathways for Covid-19



Pathways related to Covid-19 according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 TNF TLR7 STING1 NLRP3 IL6 IL2RA
2
Show member pathways
13.83 TMPRSS2 TLR7 STING1 NRP1 NLRP3 IL6
3 13.8 CCL2 CXCL10 CXCL8 F3 FURIN IL2RA
4
Show member pathways
13.45 CCL2 CXCL10 CXCL8 IL1B IL2RA IL6
5
Show member pathways
13.34 CCL2 CXCL10 CXCL8 IL1B IL2RA IL6
6
Show member pathways
13.33 TNF NRP1 IL6 IL2RA IL1B CXCL8
7
Show member pathways
13.26 TMPRSS2 TLR7 STING1 NRP1 NLRP3 FURIN
8
Show member pathways
12.87 TNF TLR7 IL6 IL2RA IL1B CXCL8
9 12.73 NLRP3 IL6 IL1B CXCL10 CCL2
10
Show member pathways
12.68 TNF NRP1 IL6 IL2RA IL1B CXCL8
11
Show member pathways
12.66 TNF IL6 IL1B F3 CXCL8
12 12.6 TNF TLR7 IL2RA IL1B CXCL10 CCL2
13
Show member pathways
12.54 TMPRSS2 TLR7 STING1 NLRP3 CTSL ACE2
14
Show member pathways
12.53 TNF TLR7 NLRP3 IL6 IL1B CXCL8
15
Show member pathways
12.47 CGAS CXCL10 IL1B IL6 STING1
16
Show member pathways
12.45 TMPRSS2 NRP1 FURIN CTSL ACE2
17
Show member pathways
12.37 TNF TLR7 IL6 IL1B CXCL8 CXCL10
18
Show member pathways
12.33 TNF IL6 IL1B CXCL8
19
Show member pathways
12.31 TNF IL6 CXCL8 CXCL10 CCL2
20 12.21 CXCL8 IL1B IL6 TNF
21
Show member pathways
11.98 IL1B IL6 TLR7 TNF
22 11.98 TNF IL6 IL1B CXCL8 CCL2
23 11.94 TNF IL6 IL1B CXCL8 CXCL10 CCL2
24 11.92 TNF IL2RA IL1B CXCL8
25
Show member pathways
11.87 TLR7 IL6 IL1B
26
Show member pathways
11.83 IL6 CXCL8 CCL2 ACE2
27 11.81 TNF IL2RA IL1B
28 11.78 TNF IL6 IL1B CXCL8 CCL2
29 11.76 TNF TLR7 IL6
30 11.76 TNF TLR7 NRP1 IL6 IL1B
31
Show member pathways
11.75 CGAS F3 IL1B NLRP3 STING1 TNF
32 11.74 IL6 IL2RA IL1B
33 11.74 IL6 CXCL8 CCL2
34
Show member pathways
11.73 TNF IL2RA CXCL8
35
Show member pathways
11.72 TNF IL6 IL1B CXCL8
36 11.71 TNF TLR7 IL6 CXCL8
37 11.69 TNF IL6 IL1B
38 11.67 TNF IL6 IL1B CXCL8 CCL2
39 11.61 CCL2 CXCL8 IL6 TNF
40 11.57 TNF IL1B CCL2
41 11.57 TLR7 IL2RA CXCL10 CCL2
42 11.56 TNF TLR7 CXCL8 CCL2 ACE2
43 11.55 TNF IL6 CCL2
44 11.54 TNF IL6 IL1B
45 11.51 CCL2 CXCL10 IL6 TNF
46 11.47 TNF IL6 IL1B CXCL8 CXCL10 CCL2
47
Show member pathways
11.46 NLRP3 IL6 CTSL ACE
48 11.42 IL6 CXCL8 CCL2
49 11.41 TNF IL6 IL1B
50 11.37 TNF IL6 IL1B

GO Terms for Covid-19

Cellular components related to Covid-19 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.02 TNF NRP1 IL6 IL1B FURIN F3
2 extracellular region GO:0005576 9.75 ACE ACE2 CCL2 CTSL CXCL10 CXCL8

Biological processes related to Covid-19 according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA-binding transcription factor activity GO:0051091 10.24 TNF STING1 IL6 IL1B
2 MAPK cascade GO:0000165 10.2 TNF TLR7 IL1B CCL2
3 viral entry into host cell GO:0046718 10.2 NRP1 DPP4 CTSL ACE2
4 defense response to Gram-positive bacterium GO:0050830 10.19 IL1B IL6 NLRP3 TNF
5 positive regulation of interleukin-6 production GO:0032755 10.19 TNF TLR7 IL6 IL1B
6 defense response to virus GO:0051607 10.18 TLR7 STING1 NLRP3 IL6 CXCL10 CGAS
7 neutrophil chemotaxis GO:0030593 10.17 IL1B CXCL8 CXCL10 CCL2
8 regulation of inflammatory response GO:0050727 10.15 TNF STING1 NLRP3 ACE2
9 regulation of insulin secretion GO:0050796 10.14 TNF IL6 IL1B
10 lipopolysaccharide-mediated signaling pathway GO:0031663 10.12 TNF IL1B CCL2
11 cellular response to virus GO:0098586 10.1 TLR7 NLRP3 IL6 CXCL10
12 cellular response to organic cyclic compound GO:0071407 10.1 TNF STING1 IL1B CCL2
13 negative regulation of neurogenesis GO:0050768 10.05 TNF IL6 IL1B
14 positive regulation of inflammatory response GO:0050729 10.02 TNF TLR7 NLRP3 IL1B ACE
15 positive regulation of glial cell proliferation GO:0060252 10.01 IL1B IL6 TNF
16 positive regulation of membrane protein ectodomain proteolysis GO:0051044 10 TNF IL1B FURIN
17 positive regulation of chemokine production GO:0032722 10 IL1B IL6 TLR7 TNF
18 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.96 ACE2 ACE
19 positive regulation of interleukin-8 production GO:0032757 9.96 TNF TLR7 IL6 IL1B F3
20 positive regulation of fever generation GO:0031622 9.95 TNF IL1B
21 cellular response to interleukin-17 GO:0097398 9.93 IL1B CXCL10
22 defense response GO:0006952 9.93 TNF NLRP3 CXCL8 CXCL10
23 immune response GO:0006955 9.93 TNF TLR7 IL6 IL2RA IL1B CXCL8
24 viral life cycle GO:0019058 9.92 ACE2 FURIN
25 sequestering of triglyceride GO:0030730 9.92 IL1B TNF
26 angiogenesis involved in coronary vascular morphogenesis GO:0060978 9.91 ACE NRP1
27 positive regulation of neuroinflammatory response GO:0150078 9.91 TNF IL6 IL1B
28 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.88 IL1B TNF
29 receptor-mediated endocytosis of virus by host cell GO:0019065 9.88 DPP4 CTSL ACE2
30 negative regulation of gap junction assembly GO:1903597 9.85 IL1B ACE
31 vascular endothelial growth factor production GO:0010573 9.8 IL1B IL6 TNF
32 cellular response to lipopolysaccharide GO:0071222 9.77 CCL2 CXCL10 CXCL8 IL1B IL6 NLRP3
33 response to external stimulus GO:0009605 9.69 TLR7 CXCL8 CXCL10
34 inflammatory response GO:0006954 9.58 TNF TLR7 NLRP3 IL6 IL2RA IL1B

Molecular functions related to Covid-19 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.86 TNF FURIN F3 DPP4
2 peptidase activity GO:0008233 9.56 TMPRSS2 FURIN DPP4 CTSL ACE2 ACE
3 peptidyl-dipeptidase activity GO:0008241 9.46 ACE2 ACE
4 cytokine activity GO:0005125 9.28 TNF IL6 IL1B CXCL8 CXCL10 CCL2

Sources for Covid-19

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....